The Long Arc of Neuroscience Innovation: Lessons from Two Decades Across Discovery, Development, and Commercialization

When I first entered the neuroscience field over twenty years ago, we weren't talking about artificial intelligence.

Gene therapy was still considered experimental.

Neurodegenerative diseases were widely viewed as some of the most difficult problems in medicine.

Looking back today, what strikes me isn't simply how much the science has advanced.

It's how many different vantage points I've had the privilege of experiencing along the journey.

I've seen neurological disease through the eyes of a discovery scientist.

Through translational biology.

Through animal model development.

Through business development.

Through clinical development.

And ultimately through commercialization.

Each stage teaches you something different about what it really takes to move scientific ideas toward patients.

Learning Where Discovery Begins

Early in my career, I had the opportunity to work on programs involving Alzheimer's disease and Huntington's disease during a period when gene therapy itself was still finding its footing.

At Ceregene, we were among the pioneers attempting to harness gene therapy for devastating neurological disorders.

Those years taught me that neuroscience is unlike almost every other therapeutic area.

You aren't simply trying to inhibit an enzyme.

Or block a receptor.

You're trying to preserve identity.

Memory.

Movement.

Independence.

The biology is extraordinarily complex.

The patients remind you every day why the work matters.

Discovery Is Only the Beginning

Like many scientists entering biotechnology, I initially believed that discovering a promising therapeutic candidate represented the hardest part.

Experience taught me otherwise.

Over the years, I had opportunities to contribute across the development continuum—from early hit-to-lead discovery and translational research through animal model evaluation, external innovation, strategic partnerships, and later-stage clinical development.

At Eli Lilly, I saw firsthand how difficult it is to translate compelling biology into medicines capable of surviving the realities of clinical development.

At Denovo Biopharma, I gained another perspective: how precision medicine, biomarkers, and patient stratification increasingly determine whether innovative therapies ultimately succeed or fail.

Each stage of development introduces different scientific questions.

Different operational challenges.

Different commercial realities.

Innovation isn't a straight line.

It's an ecosystem.

Alzheimer's: A New Way of Thinking About Protection

Recently, researchers reported a remarkable case involving a man genetically destined to develop familial Alzheimer's disease decades earlier than normal.

Despite carrying a mutation that almost invariably causes early-onset Alzheimer's, he remained cognitively healthy for many years longer than expected because of an extraordinarily rare protective mutation affecting the RELN pathway. Investigators found that this mutation appeared to preserve key memory-related brain regions despite extensive Alzheimer's pathology elsewhere, offering new clues into how resilience—not simply pathology—may influence disease progression.

What fascinates me isn't merely the mutation itself.

It's what it represents.

For decades, Alzheimer's research focused primarily on removing pathology.

Now we're increasingly asking a different question:

How does the brain resist pathology?

That subtle shift in thinking may ultimately prove transformative.

Huntington's Disease: Watching Gene Therapy Mature

The Huntington's disease community recently celebrated another milestone that would have seemed almost unimaginable when I first entered the field.

An experimental gene therapy using a viral vector to deliver microRNA directly into the brain demonstrated encouraging early clinical results, with treated patients showing substantially slower cognitive and motor decline over three years compared with untreated patients. While these findings remain early and require confirmation in larger trials, they represent one of the strongest signals yet that gene therapy may meaningfully alter the course of Huntington's disease.

Reading those results brought back memories.

Not because they validated any single program I worked on.

But because they validated an entire scientific direction.

Many of us believed, years ago, that directly modifying biology inside the brain could someday become reality.

Today, we're beginning to see glimpses of that future.

Twenty Years of Convergence

The most exciting aspect of neuroscience today isn't any single technology.

It's convergence.

Gene therapy.

RNA therapeutics.

Artificial intelligence.

Spatial biology.

Digital pathology.

Advanced neuroimaging.

Single-cell sequencing.

Protein engineering.

Precision medicine.

Each discipline contributes part of the solution.

None succeeds in isolation.

That lesson extends beyond neuroscience.

The future of drug development will belong to organizations capable of integrating multiple technologies rather than mastering only one.

Why External Innovation Matters

Working across discovery research, preclinical development, strategic partnerships, and clinical programs has reinforced one belief.

The most valuable innovation rarely originates entirely inside one organization.

Academic laboratories uncover biology.

Biotechnology companies build novel platforms.

Large pharmaceutical companies contribute development expertise, manufacturing capability, regulatory infrastructure, and commercial scale.

Patients contribute something even more important.

Hope.

The role of external innovation is to connect those pieces.

Not simply to license technologies.

To accelerate learning.

Looking Forward

When I think back to the early days of gene therapy, I remember how ambitious many of those conversations felt.

Today, many of those ideas are entering clinical practice.

Not because the science became easier.

Because thousands of scientists, physicians, engineers, entrepreneurs, patients, and investors continued building on each other's discoveries over decades.

That is perhaps the greatest lesson neuroscience has taught me.

Innovation is rarely a breakthrough.

It is usually a relay race.

I've been fortunate to carry the baton from several different positions along that course.

And if the recent advances in Alzheimer's disease and Huntington's disease are any indication, I believe the next generation of discoveries may finally begin delivering on promises that inspired many of us to enter neuroscience in the first place.